FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310368088> ?p ?o ?g. }

• W4310368088 endingPage "225" @default.
• W4310368088 startingPage "217" @default.
• W4310368088 abstract "Key Points The entire extracellular domain of thrombospondin type-1 domain 7A (THSD7A) in the luciferase immunoprecipitation system immunoassay was required to detect autoantibodies with high sensitivity in membranous nephropathy (MN). In THSD7A-seropositive MN patients, changes in antibody levels precede changes in clinical status. Seropositive THSD7A antibodies were detected in some patients with MN considered to be secondary to autoimmunity or cancer. Background Pathogenic autoantibodies against thrombospondin type-1 domain 7A (THSD7A) are present in approximately 3% of patients with membranous nephropathy (MN). Compared with PLA2R antibodies, less is known about THSD7A autoantibodies (ABs) because of the relative rarity and the lack of a commercially available quantitative immunoassay. Methods In this study, we describe the development and validation of a highly quantitative luciferase immunoprecipitation system (LIPS) assay for detecting THSD7A ABs and used it to study dominant THSD7A epitopes, disease associations, and monitoring disease activity. The Department of Defense Serum Repository (DODSR) was then used to analyze THSD7A AB in 371 longitudinal serum samples collected before clinical diagnosis of MN from 110 PLA2R-negative MN subjects. Results LIPS analysis demonstrated that a near full-length THSD7A (amino acids 1–1656) detected robust autoantibody levels in all known seropositive MN patients with 100% sensitivity and specificity compared with ELISA and/or Western blotting. Most of the THSD7A-seropositive subjects in our pilot cohort had evidence of coexisting autoimmunity or cancer. Moreover, three THSD7A-seropositive patients undergoing immunosuppressive therapy showed longitudinal autoantibody levels that tracked clinical status. Additional epitope analysis of two smaller protein THSD7A fragments spanning amino acids 1-416 and 1-671 demonstrated lower sensitivity of 32% and 44%, respectively. In the DODSR cohort, THSD7A seropositivity was detected in 4.5% of PLA2R-negative MN patients. In one primary and in one secondary MN-associated with cancer, THSD7A ABs were detectable <1 month before biopsy-proven diagnosis. In addition, three patients with lupus membranous nephropathy had detectable THSD7A ABs years before hypoalbuminemia and biopsy-proven diagnosis. Conclusions Although further studies are needed to explore the significance of THSD7A ABs in lupus membranous nephropathy, this study describes a novel, highly sensitive LIPS immunoassay for detecting THSD7A ABs and adds to the existing literature on THSD7A-associated MN. Clinical Trial registry name and registration number: NCT00977977; registration date: September 16, 2009." @default.
• W4310368088 created "2022-12-09" @default.
• W4310368088 creator A5004456379 @default.
• W4310368088 creator A5007740460 @default.
• W4310368088 creator A5017276976 @default.
• W4310368088 creator A5034379903 @default.
• W4310368088 creator A5041450311 @default.
• W4310368088 creator A5050651970 @default.
• W4310368088 creator A5052901007 @default.
• W4310368088 creator A5062055687 @default.
• W4310368088 creator A5084604936 @default.
• W4310368088 date "2022-11-29" @default.
• W4310368088 modified "2023-09-25" @default.
• W4310368088 title "Prediagnostic Appearance of Thrombospondin Type-1 Domain 7A Autoantibodies in Membranous Nephropathy" @default.
• W4310368088 cites W1970834742 @default.
• W4310368088 cites W2004034968 @default.
• W4310368088 cites W2083760961 @default.
• W4310368088 cites W2166822765 @default.
• W4310368088 cites W2494290614 @default.
• W4310368088 cites W2520057597 @default.
• W4310368088 cites W2532400747 @default.
• W4310368088 cites W2550278183 @default.
• W4310368088 cites W2583427269 @default.
• W4310368088 cites W2617482626 @default.
• W4310368088 cites W2743994075 @default.
• W4310368088 cites W2782911007 @default.
• W4310368088 cites W2792441704 @default.
• W4310368088 cites W2795802461 @default.
• W4310368088 cites W2883290746 @default.
• W4310368088 cites W2904109524 @default.
• W4310368088 cites W2917492117 @default.
• W4310368088 cites W2991139586 @default.
• W4310368088 cites W2995516475 @default.
• W4310368088 cites W3041326149 @default.
• W4310368088 cites W3091916585 @default.
• W4310368088 cites W3121647095 @default.
• W4310368088 cites W3124083971 @default.
• W4310368088 cites W3163371460 @default.
• W4310368088 cites W3170737975 @default.
• W4310368088 cites W3188842792 @default.
• W4310368088 doi "https://doi.org/10.34067/kid.0005112022" @default.
• W4310368088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36821613" @default.
• W4310368088 hasPublicationYear "2022" @default.
• W4310368088 type Work @default.
• W4310368088 citedByCount "1" @default.
• W4310368088 countsByYear W43103680882023 @default.
• W4310368088 crossrefType "journal-article" @default.
• W4310368088 hasAuthorship W4310368088A5004456379 @default.
• W4310368088 hasAuthorship W4310368088A5007740460 @default.
• W4310368088 hasAuthorship W4310368088A5017276976 @default.
• W4310368088 hasAuthorship W4310368088A5034379903 @default.
• W4310368088 hasAuthorship W4310368088A5041450311 @default.
• W4310368088 hasAuthorship W4310368088A5050651970 @default.
• W4310368088 hasAuthorship W4310368088A5052901007 @default.
• W4310368088 hasAuthorship W4310368088A5062055687 @default.
• W4310368088 hasAuthorship W4310368088A5084604936 @default.
• W4310368088 hasBestOaLocation W43103680881 @default.
• W4310368088 hasConcept C104317684 @default.
• W4310368088 hasConcept C109523444 @default.
• W4310368088 hasConcept C126322002 @default.
• W4310368088 hasConcept C153911025 @default.
• W4310368088 hasConcept C159654299 @default.
• W4310368088 hasConcept C163764329 @default.
• W4310368088 hasConcept C167814343 @default.
• W4310368088 hasConcept C195616568 @default.
• W4310368088 hasConcept C203014093 @default.
• W4310368088 hasConcept C2775946357 @default.
• W4310368088 hasConcept C2780091579 @default.
• W4310368088 hasConcept C2780130043 @default.
• W4310368088 hasConcept C2780368995 @default.
• W4310368088 hasConcept C2780420688 @default.
• W4310368088 hasConcept C55493867 @default.
• W4310368088 hasConcept C55728118 @default.
• W4310368088 hasConcept C71924100 @default.
• W4310368088 hasConcept C85265743 @default.
• W4310368088 hasConcept C86803240 @default.
• W4310368088 hasConceptScore W4310368088C104317684 @default.
• W4310368088 hasConceptScore W4310368088C109523444 @default.
• W4310368088 hasConceptScore W4310368088C126322002 @default.
• W4310368088 hasConceptScore W4310368088C153911025 @default.
• W4310368088 hasConceptScore W4310368088C159654299 @default.
• W4310368088 hasConceptScore W4310368088C163764329 @default.
• W4310368088 hasConceptScore W4310368088C167814343 @default.
• W4310368088 hasConceptScore W4310368088C195616568 @default.
• W4310368088 hasConceptScore W4310368088C203014093 @default.
• W4310368088 hasConceptScore W4310368088C2775946357 @default.
• W4310368088 hasConceptScore W4310368088C2780091579 @default.
• W4310368088 hasConceptScore W4310368088C2780130043 @default.
• W4310368088 hasConceptScore W4310368088C2780368995 @default.
• W4310368088 hasConceptScore W4310368088C2780420688 @default.
• W4310368088 hasConceptScore W4310368088C55493867 @default.
• W4310368088 hasConceptScore W4310368088C55728118 @default.
• W4310368088 hasConceptScore W4310368088C71924100 @default.
• W4310368088 hasConceptScore W4310368088C85265743 @default.
• W4310368088 hasConceptScore W4310368088C86803240 @default.
• W4310368088 hasFunder F4320320883 @default.
• W4310368088 hasIssue "2" @default.
• W4310368088 hasLocation W43103680881 @default.

• next